Intravenous iron supplementation therapy

Molecular Aspects of Medicine

Volumn 75, Issue , 2020, Pages

  Schaefer, Benedikt ^a   Meindl, Eva ^a   Wagner, Sonja ^a   Tilg, Herbert ^a   Zoller, Heinz ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; FERRIC CARBOXYMALTOSE; FERRIC GLUCONATE; FERRITIN; FIBROBLAST GROWTH FACTOR 23; HEMOGLOBIN; IRON DEXTRAN; IRON SACCHARATE; TRANSFERRIN; IRON;

BONE PAIN; DIET SUPPLEMENTATION; DISEASE SEVERITY; FERRITIN BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOCALCEMIA; HYPOPHOSPHATEMIA; IRON DEFICIENCY ANEMIA; IRON INTAKE; IRON THERAPY; NONHUMAN; OSTEOMALACIA; PATIENT SELECTION; QUALITY OF LIFE; REVIEW; SECONDARY HYPERPARATHYROIDISM; TREATMENT RESPONSE; VITAMIN D DEFICIENCY; DIETARY SUPPLEMENT; PROSPECTIVE STUDY;

ANEMIA, IRON-DEFICIENCY; DIETARY SUPPLEMENTS; HUMANS; IRON; PROSPECTIVE STUDIES; QUALITY OF LIFE;

EID: 85084814794     PISSN: 00982997     EISSN: 18729452     Source Type: Journal    
DOI: 10.1016/j.mam.2020.100862     Document Type: Review

References (68)

1. Aapro, M., Beguin, Y., Bokemeyer, C., Dicato, M., Gascon, P., Glaspy, J., Hofmann, A., Link, H., Littlewood, T., Ludwig, H., Osterborg, A., Pronzato, P., Santini, V., Schrijvers, D., Stauder, R., Jordan, K., Herrstedt, J., Committee, E.G., Management of anaemia and iron deficiency in patients with cancer: ESMO Clinical Practice Guidelines. Ann. Oncol., 29(Suppl. 4), 2018, iv271.
2. Adkinson, N.F., Strauss, W.E., Macdougall, I.C., Bernard, K.E., Auerbach, M., Kaper, R.F., Chertow, G.M., Krop, J.S., Comparative safety of intravenous ferumoxytol versus ferric carboxymaltose in iron deficiency anemia: a randomized trial. Am. J. Hematol. 93:5 (2018), 683–690.
3. Administration, F.a.D., FDA Drug Safety Communication: FDA Strengthens Warnings and Changes Prescribing Instructions to Decrease the Risk of Serious Allergic Reactions with Anemia Drug Feraheme (Ferumoxytol). 2015.
4. Agency, E.M., New Recommendations to Manage Risk of Allergic Reactions with Intravenous Iron-Containing Medicines. 2013 (London).
5. Allergan, Ireland. INFeD (IRON DEXTRAN INJECTION USP)) [package Insert]. 2009, U.S. Food and Drug Administration website Accessed March 19, 2020 https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/017441s171lbl.pdf.
6. Amag Pharmaceuticals, Inc. Waltham, MA. FERAHEME (Ferumoxytol Injection) [package Insert]. 2019, U.S. Food and Drug Administration Accessed March 19, 2020 https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022180s023lbl.pdf.
7. American Society of Anesthesiologists Task Force on Perioperative Blood, M., Practice guidelines for perioperative blood management: an updated report by the American society of anesthesiologists task force on perioperative blood management*. Anesthesiology 122:2 (2015), 241–275.
8. Anderson, G.J., Frazer, D.M., Current understanding of iron homeostasis. Am. J. Clin. Nutr. 106:Suppl. 6 (2017), 1559S–1566S.
9. Anker, S.D., Comin Colet, J., Filippatos, G., Willenheimer, R., Dickstein, K., Drexler, H., Luscher, T.F., Bart, B., Banasiak, W., Niegowska, J., Kirwan, B.A., Mori, C., von Eisenhart Rothe, B., Pocock, S.J., Poole-Wilson, P.A., Ponikowski, P., Investigators, F.-H.T., Ferric carboxymaltose in patients with heart failure and iron deficiency. N. Engl. J. Med. 361:25 (2009), 2436–2448.
10. Auerbach, M., Henry, D., Derman, R.J., Achebe, M.M., Thomsen, L.L., Glaspy, J., A prospective, multi-center, randomized comparison of iron isomaltoside 1000 versus iron sucrose in patients with iron deficiency anemia; the FERWON-IDA trial. Am. J. Hematol. 94:9 (2019), 1007–1014.
11. Avni, T., Bieber, A., Grossman, A., Green, H., Leibovici, L., Gafter-Gvili, A., The safety of intravenous iron preparations: systematic review and meta-analysis. Mayo Clin. Proc. 90:1 (2015), 12–23.
12. Bhandari, S., Pereira, D.I.A., Chappell, H.F., Drakesmith, H., Intravenous irons: from basic science to clinical practice. Pharmaceuticals, 11(3), 2018.
13. Bhandari, S., Kalra, P.A., Berkowitz, M., Belo, D., Thomsen, L.L., Wolf, M., Safety and efficacy of iron isomaltoside 1000/ferric derisomaltose versus iron sucrose in patients with chronic kidney disease: the FERWON-NEPHRO randomized, open-label, comparative trial. Nephrol. Dial. Transplant., 2020.
14. Cartwright, G.E., Lauritsen, M.A., et al. The anemia of infection; hypoferremia, hypercupremia, and alterations in porphyrin metabolism in patients. J. Clin. Invest. 25 (1946), 65–80.
15. Chandler, G., Harchowal, J., Macdougall, I.C., Intravenous iron sucrose: establishing a safe dose. Am. J. Kidney Dis. 38:5 (2001), 988–991.
16. De Hert, S., Imberger, G., Carlisle, J., Diemunsch, P., Fritsch, G., Moppett, I., Solca, M., Staender, S., Wappler, F., Smith, A., Task Force on Preoperative Evaluation of the Adult Noncardiac Surgery Patient of the European Society of, A. Preoperative evaluation of the adult patient undergoing non-cardiac surgery: guidelines from the European Society of Anaesthesiology. Eur. J. Anaesthesiol. 28:10 (2011), 684–722.
17. DeLoughery, T.G., Risk of anaphylaxis with intravenous iron products. J. Am. Med. Assoc., 315(20), 2016, 2232.
18. Dignass, A.U., Gasche, C., Bettenworth, D., Birgegard, G., Danese, S., Gisbert, J.P., Gomollon, F., Iqbal, T., Katsanos, K., Koutroubakis, I., Magro, F., Savoye, G., Stein, J., Vavricka, S., European, C.s., Colitis, O., European consensus on the diagnosis and management of iron deficiency and anaemia in inflammatory bowel diseases. J Crohns Colitis 9:3 (2015), 211–222.
19. Fishbane, S., Ungureanu, V.D., Maesaka, J.K., Kaupke, C.J., Lim, V., Wish, J., The safety of intravenous iron dextran in hemodialysis patients. Am. J. Kidney Dis. 28:4 (1996), 529–534.
20. Geisser, P., Burckhardt, S., The pharmacokinetics and pharmacodynamics of iron preparations. Pharmaceutics 3:1 (2011), 12–33.
21. Goddard, A.F., James, M.W., McIntyre, A.S., Scott, B.B., British Society of, G., Guidelines for the management of iron deficiency anaemia. Gut 60:10 (2011), 1309–1316.
22. Goetsch, A.T., Moore, C.V., Minnich, V., Observations on the effect of massive doses of iron given intravenously to patients with hypochromic anemia. Blood 1 (1946), 129–142.
23. Jahn, M.R., Andreasen, H.B., Futterer, S., Nawroth, T., Schunemann, V., Kolb, U., Hofmeister, W., Munoz, M., Bock, K., Meldal, M., Langguth, P., A comparative study of the physicochemical properties of iron isomaltoside 1000 (Monofer), a new intravenous iron preparation and its clinical implications. Eur. J. Pharm. Biopharm. : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V 78:3 (2011), 480–491.
24. Kalra, P.A., Effectiveness of Intravenous Iron Treatment vs Standard Care in Patients with Heart Failure and Iron Deficiency: a Randomised, Open-Label Multicentre Trial (IRONMAN). 2015.
25. Kamanna, V.S., Ganji, S.H., Shelkovnikov, S., Norris, K., Vaziri, N.D., Iron sucrose promotes endothelial injury and dysfunction and monocyte adhesion/infiltration. Am. J. Nephrol. 35:2 (2012), 114–119.
26. Kdoqi, KDOQI Clinical Practice Guideline and Clinical Practice Recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target. Am. J. Kidney Dis. 50:3 (2007), 471–530.
27. Kemp, S.F., Lockey, R.F., Simons, F.E., World Allergy Organization ad hoc Committee on Epinephrine in, A. Epinephrine: the drug of choice for anaphylaxis-a statement of the world allergy organization. World Allergy Organ. J. 1:7 Suppl. l (2008), S18–S26.
28. Knutson, M.D., Non-transferrin-bound iron transporters. Free Radic. Biol. Med. 133 (2019), 101–111.
29. Koch, T.A., Myers, J., Goodnough, L.T., Intravenous iron therapy in patients with iron deficiency anemia: dosing considerations. Anemia, 2015, 2015, 763576.
30. Kuo, K.-L., Hung, S.-C., Lee, T.-S., Tarng, D.-C., Iron sucrose accelerates early atherogenesis by increasing superoxide production and upregulating adhesion molecules in CKD. J. Am. Soc. Nephrol. 25:11 (2014), 2596–2606.
31. Levy, J.E., Jin, O., Fujiwara, Y., Kuo, F., Andrews, N.C., Transferrin receptor is necessary for development of erythrocytes and the nervous system. Nat. Genet. 21:4 (1999), 396–399.
32. Lim, W., Afif, W., Knowles, S., Lim, G., Lin, Y., Mothersill, C., Nistor, I., Rehman, F., Song, C., Xenodemetropoulos, T., Canadian expert consensus: management of hypersensitivity reactions to intravenous iron in adults. Vox Sang. 114:4 (2019), 363–373.
33. Marchasin, S., Wallerstein, R.O., The treatment of iron-deficiency anemia with intravenous iron dextran. Blood 23 (1964), 354–358.
34. McMurray, J., Parfrey, P., KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease. 2012, Kidney international, 1–335 Supplement 2.
35. Michael, B., Coyne, D.W., Fishbane, S., Folkert, V., Lynn, R., Nissenson, A.R., Agarwal, R., Eschbach, J.W., Fadem, S.Z., Trout, J.R., Strobos, J., Warnock, D.G., Ferrlecit Publication, C., Sodium ferric gluconate complex in hemodialysis patients: adverse reactions compared to placebo and iron dextran. Kidney Int. 61:5 (2002), 1830–1839.
36. Muckenthaler, M.U., Rivella, S., Hentze, M.W., Galy, B., A red carpet for iron metabolism. Cell 168:3 (2017), 344–361.
37. Munoz, M., Acheson, A.G., Auerbach, M., Besser, M., Habler, O., Kehlet, H., Liumbruno, G.M., Lasocki, S., Meybohm, P., Rao Baikady, R., Richards, T., Shander, A., So-Osman, C., Spahn, D.R., Klein, A.A., International consensus statement on the peri-operative management of anaemia and iron deficiency. Anaesthesia 72:2 (2017), 233–247.
38. Nathell, L., Gohlke, A., Wohlfeil, S., Reported severe hypersensitivity reactions after intravenous iron administration in the European economic area (EEA) before and after implementation of risk minimization measures. Drug Saf. 43:1 (2020), 35–43.
39. Neiser, S., Rentsch, D., Dippon, U., Kappler, A., Weidler, P.G., Gottlicher, J., Steininger, R., Wilhelm, M., Braitsch, M., Funk, F., Philipp, E., Burckhardt, S., Physico-chemical properties of the new generation IV iron preparations ferumoxytol, iron isomaltoside 1000 and ferric carboxymaltose. Biometals 28:4 (2015), 615–635.
40. Nissim, J.A., Robson, J.M., Preparation and standardization of saccharated iron oxide for intra venous administration. Lancet 1:6556 (1949), 686–689.
41. Pai, A.B., Complexity of intravenous iron nanoparticle formulations: implications for bioequivalence evaluation. Ann. N. Y. Acad. Sci. 1407:1 (2017), 17–25.
42. Pavord, S., Myers, B., Robinson, S., Allard, S., Strong, J., Oppenheimer, C., British Committee for Standards in, H. UK guidelines on the management of iron deficiency in pregnancy. Br. J. Haematol. 156:5 (2012), 588–600.
43. Peyrin-Biroulet, L., Williet, N., Cacoub, P., Guidelines on the diagnosis and treatment of iron deficiency across indications: a systematic review. Am. J. Clin. Nutr. 102:6 (2015), 1585–1594.
44. Pharmacosmos A/S, Denmark. MONOFERRIC (Ferric Derisomaltose) [package Insert]. 2018, U.S. Food and Drug Administration website Accessed March 19, 2020 https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208171s000lbl.pdf.
45. Polson, C.J., The fate of colloidal iron administered intravenously. J. Pathol. 31:3 (1928), 445–460.
46. Ponikowski, P., van Veldhuisen, D.J., Comin-Colet, J., Ertl, G., Komajda, M., Mareev, V., McDonagh, T., Parkhomenko, A., Tavazzi, L., Levesque, V., Mori, C., Roubert, B., Filippatos, G., Ruschitzka, F., Anker, S.D., Investigators, C.-H., Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiencydagger. Eur. Heart J. 36:11 (2015), 657–668.
47. Ponikowski, P., Voors, A.A., Anker, S.D., Bueno, H., Cleland, J.G., Coats, A.J., Falk, V., Gonzalez-Juanatey, J.R., Harjola, V.P., Jankowska, E.A., Jessup, M., Linde, C., Nihoyannopoulos, P., Parissis, J.T., Pieske, B., Riley, J.P., Rosano, G.M., Ruilope, L.M., Ruschitzka, F., Rutten, F.H., van der Meer, P., Authors/Task Force, M., Document, R., 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur. J. Heart Fail. 18:8 (2016), 891–975.
48. Prats, M., Font, R., Garcia-Ruiz, C., Cabre, C., Munoz-Cortes, M., Nogues, M.R., Jariod, M., Romeu, M., Martinez-Vea, A., Acute and sub-acute effect of ferric carboxymaltose on inflammation and adhesion molecules in patients with predialysis chronic renal failure. Nefrologia 33:3 (2013), 355–361.
49. Rampton, D., Folkersen, J., Fishbane, S., Hedenus, M., Howaldt, S., Locatelli, F., Patni, S., Szebeni, J., Weiss, G., Hypersensitivity reactions to intravenous iron: guidance for risk minimization and management. Haematologica 99:11 (2014), 1671–1676.
50. Sanofi-aventis U.S. LLC. Ferrlecit (Sodium Ferric Gluconate Complex in Sucrose Injection) [package Insert]. 2013, U.S. Food and Drug Administration Accessed March 19, 2020 https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020955s013s015lbl.pdf.
51. Simons, F.E., Ardusso, L.R., Bilo, M.B., El-Gamal, Y.M., Ledford, D.K., Ring, J., Sanchez-Borges, M., Senna, G.E., Sheikh, A., Thong, B.Y., World Allergy, O., World allergy organization guidelines for the assessment and management of anaphylaxis. World Allergy Organ. J. 4:2 (2011), 13–37.
52. Simons, F.E., Ebisawa, M., Sanchez-Borges, M., Thong, B.Y., Worm, M., Tanno, L.K., Lockey, R.F., El-Gamal, Y.M., Brown, S.G., Park, H.S., Sheikh, A., 2015 update of the evidence base: world Allergy Organization anaphylaxis guidelines. World Allergy Organ. J., 8(1), 2015, 32.
53. Simpson, R.J., Konijn, A.M., Lombard, M., Raja, K.B., Salisbury, J.R., Peters, T.J., Tissue iron loading and histopathological changes in hypotransferrinaemic mice. J. Pathol. 171:3 (1993), 237–244.
54. Szebeni, J., Fishbane, S., Hedenus, M., Howaldt, S., Locatelli, F., Patni, S., Rampton, D., Weiss, G., Folkersen, J., Hypersensitivity to intravenous iron: classification, terminology, mechanisms and management. Br. J. Pharmacol. 172:21 (2015), 5025–5036.
55. Theurl, I., Theurl, M., Seifert, M., Mair, S., Nairz, M., Rumpold, H., Zoller, H., Bellmann-Weiler, R., Niederegger, H., Talasz, H., Weiss, G., Autocrine formation of hepcidin induces iron retention in human monocytes. Blood 111:4 (2008), 2392–2399.
56. Thomas, C., Lumb, A.B., Physiology of haemoglobin. Cont. Educ. Anaesth. Crit. Care Pain 12:5 (2012), 251–256.
57. Vifor (International) Inc, Switzerland. Venofer (Iron Sucrose Injection, USP) [package Insert]. 2018, U.S. Food and Drug Administration Accessed March 19, 2020 https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021135s035lbl.pdf.
58. Vifor (International) Inc, Switzerland. INJECTAFER® (Ferric Carboxymaltose Injection), [package Insert]. 2020, U.S. Food and Drug Administration website Accessed March 19, 2020 https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203565s009lbl.pdf.
59. Vinchi, F., Porto, G., Simmelbauer, A., Altamura, S., Passos, S.T., Garbowski, M., Silva, A.M.N., Spaich, S., Seide, S.E., Sparla, R., Hentze, M.W., Muckenthaler, M.U., Atherosclerosis is aggravated by iron overload and ameliorated by dietary and pharmacological iron restriction. Eur. Heart J., 2019.
60. Wang, C., Graham, D.J., Kane, R.C., Xie, D., Wernecke, M., Levenson, M., MaCurdy, T.E., Houstoun, M., Ryan, Q., Wong, S., Mott, K., Sheu, T.C., Limb, S., Worrall, C., Kelman, J.A., Reichman, M.E., Comparative risk of anaphylactic reactions associated with intravenous iron products. J. Am. Med. Assoc. 314:19 (2015), 2062–2068.
61. Wang, C., Wong, S., Graham, D.J., Risk of anaphylaxis with intravenous iron products. J. Am. Med. Assoc. 315:20 (2016), 2232–2233.
62. Weiss, G., Ganz, T., Goodnough, L.T., Anemia of inflammation. Blood 133:1 (2019), 40–50.
63. Wennesland, R., Brown, E., Hopper, J. Jr., Hodges, J.L. Jr., Guttentag, O.E., Scott, K.G., Tucker, I.N., Bradley, B., Red cell, plasma and blood volume in healthy men measured by radiochromium (Cr51) cell tagging and hematocrit: influence of age, somatotype and habits of physical activity on the variance after regression of volumes to height and weight combined. J. Clin. Invest. 38:7 (1959), 1065–1077.
64. Wolf, M., Koch, T.A., Bregman, D.B., Effects of iron deficiency anemia and its treatment on fibroblast growth factor 23 and phosphate homeostasis in women. J. Bone Miner. Res. 28:8 (2013), 1793–1803.
65. Wolf, M., Chertow, G.M., Macdougall, I.C., Kaper, R., Krop, J., Strauss, W., Randomized trial of intravenous iron-induced hypophosphatemia. JCI Insight, 3(23), 2018.
66. Wolf, M., Rubin, J., Achebe, M., Econs, M.J., Peacock, M., Imel, E.A., Thomsen, L.L., Carpenter, T.O., Weber, T., Brandenburg, V., Zoller, H., Effects of iron isomaltoside vs ferric carboxymaltose on hypophosphatemia in iron-deficiency anemia: two randomized clinical trials. J. Am. Med. Assoc. 323:5 (2020), 432–443.
67. Yancy, C.W., Jessup, M., Bozkurt, B., Butler, J., Casey, D.E. Jr., Colvin, M.M., Drazner, M.H., Filippatos, G.S., Fonarow, G.C., Givertz, M.M., Hollenberg, S.M., Lindenfeld, J., Masoudi, F.A., McBride, P.E., Peterson, P.N., Stevenson, L.W., Westlake, C., 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American college of Cardiology/American heart association task force on clinical practice guidelines and the heart failure society of America. Circulation 136:6 (2017), e137–e161.
68. Zoller, H., Schaefer, B., Glodny, B., Iron-induced hypophosphatemia: an emerging complication. Curr. Opin. Nephrol. Hypertens. 26:4 (2017), 266–275.